C2N Diagnostics
@C2NDiagnostics
Followers
301
Following
89
Media
34
Statuses
338
C₂N Diagnostics is a specialty diagnostics company with a vision to bring Clarity Through Innovation®.
Joined October 2019
C2N Diagnostics, used in clinical trials for #Leqembi™ for #Alzheimer’s disease treatment, poised to support medical community in next steps. Health care providers begin to register to use C2N’s analytically & clinically validated blood tests. #FDA
https://t.co/iiRo1l7rg1
0
1
3
C2N announces partnership w/ @MichaelJFoxOrg to uncover new links b/w #ParkinsonsDisease #LewyBodyDementia & #AlzheimersDisease
c2n.com
ST. LOUIS — Jan. 15, 2025 — A respected organization acclaimed for their groundbreaking work with neurological diseases, C2N Diagnostics, LLC , is partnering with The Michael J. Fox Foundation For...
0
0
0
Announcing a new DxA investment in @C2NDiagnostics for over $7M—its largest investment to-date. This underscores the DxA’s commitment to developing & deploying #novel biomarkers—like #BloodTests—to transform the #Alzheimers diagnostic landscape: https://t.co/6Y0wrj3M3g
1
2
5
C2N Diagnostics has entered into a non-exclusive agreement in select markets w/ @mayocliniclabs for inclusion of C2N’s Precivity™ tests in their test offerings. https://t.co/bC6RVQJdXn
#precisionmedicine #Alzheimersdisease #MayoClinicLaboratories
c2n.com
Healthcare Providers Have Expanded Access to C2N’s Blood Tests to Better Identify Alzheimer’s Disease Pathology ST. LOUIS — June 27, 2024 — C2N Diagnostics , LLC (“C2N”), which provides exceptional...
0
0
0
Hats off to our supporters/sponsors/grantors: @MeilleurTechnologies, @LantheusNews, @EliLillyandCo, @alzassociation, @eisaiusneuro, @genentech, @RCFNeuro, @bmsnews, @Invicro, @LifeMolecular, @JNJNews, @C2NDiagnostics, @Clario, @abbvie, @QuanterixSimoa Big round of applause
0
1
11
Allston Brighton Community Fund is proud to support @ablittleleague. For over 70 years, the Allston Brighton Little League has been part of our community. We can’t wait to hear “play ball!” #baseball #littleleague #AllstonBrighton
https://t.co/mJ3M3nUIFr
0
1
1
Researchers identify new cost savings and accuracy of C₂N Diagnostics’ blood tests to enable healthcare providers to better identify Alzheimer’s disease. #CTAD23
c2n.com
Findings Presented at 16th Clinical Trials on Alzheimer's Disease Conference ST. LOUIS — Nov. 16, 2023 — Scientists, clinicians, and others taking part in the 16th Clinical Trials on Alzheimer's...
0
0
0
C2N Sr. Medical Advisor Dr. Monane will present his research @geronsociety #GSA2023 in Tampa. "Patient Age And Sex Do Not Appear To Influence Decision Making Around Biomarker Testing for Cognitive Impairment.” Session 9550: 11/12, 10:00–11:30 a.m. room 413 #GSA2023 #Alzheimers
0
0
2
Congratulations to @RandallBateman3 our CTAD Lifetime Achievement Award recipient in recognition for his pioneering work in Alzheimer's Disease Research and Plasma Biomarkers in AD diagnostics.
1
5
35
Congrats to our scientific co-founder @RandallBateman3 on receiving the @CTADconference Lifetime Achievement Award in recognition of his pioneering work in Alzheimer’s disease research and plasma biomarkers in AD diagnosis. #CTAD2023
0
2
4
C2N Diagnostics introduces next-generation fluid biomarker to the field of #Alzheimer’s disease: Test to help researchers track neurofibrillary “tau” tangle pathology. #CTAD2023
c2n.com
ST. LOUIS — Oct. 25, 2023 — C2N Diagnostics , a leader in advanced brain health diagnostics, is responding to pharmaceutical industry interest by introducing a much-desired, proprietary biomarker...
0
0
1
advancements, expansion ~@GenScript expands reagent services, adds #CircularRNA, #LipidNanoparticles formulation ~On #WorldAlzheimersDay, @C2NDiagnostics expands #bloodtest reach ~@viz_ai expands #outpatient ambulatory centers to advance trial recruitment in #HeartFailure
0
1
2
On #worldalzheimersday2023, C₂N Diagnostics’ PrecivityAD2™ blood test expands reach. The test availability through Grupo Fleury aims to help #Brazilians receive accurate, early #AlzheimersDisease #diagnosis
https://t.co/NaiwU1dsMA
#Brazil
c2n.com
Test Availability Through Grupo Fleury Aims to Help Brazilians Receive Accurate, Early Alzheimer’s Disease Diagnosis ST. LOUIS — Sept. 21, 2023 — C2N Diagnostics , a leader in advanced brain health...
0
0
0
News from @medicaldevnet about the PrecivityAD2™ blood test that aims to set a new performance standard for blood biomarkers in #Alzheimer’s disease diagnosis w/ combined measures of amyloid beta (aβ42/40) & tau protein (p-tau217/np-tau217) ratios https://t.co/wtcFKTm94L
medicaldevice-network.com
C2N Diagnostics has introduced a new assay called the PrecivityAD2 blood test to assess patients with signs and symptoms of Alzheimer’s disease.
0
0
4
.@adnewstoday reports on study published in @ANA_journals that shows the PrecivityAD® blood test significantly influences clinicians’ decisions about whether to treat people with cognitive impairments for #Alzheimer’s disease.
alzheimersnewstoday.com
The PrecivityAD blood test was found to influence doctors' decisions to treat for Alzheimer's disease in a real-world study.
0
0
1
.@FierceBiotech reports on our release of the PrecivityAD2™ blood test for clinical care, a robust #assay w/ high concordance to amyloid PET & CSF https://t.co/bu1RDt22VR
#AlzheimersDisease
fiercebiotech.com
Alzheimer’s disease blood test developer C2N Diagnostics has released a new version of its screener for beta amyloid proteins, and it’s gearing up for a nationwide rollout as public hopes rise for |...
0
0
1
C₂N Diagnostics Releases the PrecivityAD2™ Blood Test for Clinical Care, a Robust Assay with High Concordance to Amyloid PET and CSF #test #Alzheimer #dementia
https://t.co/w7vxA47l92
precivityad.com
PrecivityAD2 Aims to Set a New Performance Standard for Blood Biomarkers in Alzheimer’s Disease Diagnosis With Combined Measures of Amyloid Beta (Aβ42/40) and Tau Protein (p-tau217/np-tau217) Ratios ...
0
3
2
#clinicaldata ~@Masimo SedLine could improve #brain monitoring during #endoscopy, study says ~@spinex_official's #neuromodulation #tech ‘game-changing’ for children with #cerebralpalsy ~#RWE shows promise for @C2NDiagnostics' PrecivityAD® #BloodTest
0
1
1
New real-world evidence released by ADDF-funded @C2NDiagnostics shows that their PrecivityAD2 beta-amyloid #BloodTest helped correctly diagnose #Alzheimers in 87% of cases as compared to using standard assessment tools. Read more about the findings here:
c2n.com
Company Sees the Soon-to-be-Released PrecivityAD2™ Blood Test as Reliable Replacement for CSF and PET as Alzheimer’s Disease Diagnosis Guideline Updating Begins ST. LOUIS — Aug. 2, 2023 — C2N...
0
2
2